Research graph
References from Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Thyroid disorders induced by immune checkpoint inhibitors
10.1007/s12020-024-03718-2 · 2024 · External reference
Updated estimates of eligibility and response: immune checkpoint inhibitors
10.1200/jco.2024.42.16_suppl.e14613 · 2024 · External reference
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
10.1007/s12020-024-04050-5 · 2025 · External reference
Immune-related adverse events and immunotherapy efficacy in patients with cancer: a retrospective study
10.1200/jco.2022.40.16_suppl.2654 · 2022 · External reference
Checkpoint inhibitor-associated autoimmune diabetes Mellitus is characterized by C-peptide loss and pancreatic atrophy
10.1210/clinem/dgad685 · 2024 · External reference
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
10.1016/s1470-2045(16)30366-7 · 2016 · External reference
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma
10.1056/nejmoa2407417 · 2025 · External reference
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
10.1530/eje-19-0291 · 2019 · External reference
Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes Mellitus (CIADM): a systematic review and delineation from type 1 diabetes
10.2337/dc22-2202 · 2023 · External reference
Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors
10.2337/dbi18-0002 · 2018 · External reference
Identification of immune checkpoint inhibitor-induced diabetes
10.1001/jamaoncol.2024.3104 · 2024 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
10.1200/jco.21.01440 · 2021 · External reference
Clinical diagnosis of graves’ or non-graves’ hyperthyroidism compared to TSH receptor antibody test
10.1530/ec-18-0082 · 2018 · External reference
[Graves disease with negative TSH receptor antibodies: a presentation of 5 cases]
2020 · External reference
Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis
10.3389/fonc.2021.749064 · 2021 · External reference
PD-L1 Inhibitor-Induced thyroiditis is associated with better overall survival in cancer patients
10.1089/thy.2019.0250 · 2020 · External reference
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
10.1016/j.esmoop.2023.100787 · 2023 · External reference
